Benzinga
20 Mar 2026, 15:07 UTC · 27w ago
Verdict
Headline takes no side. We score AIM +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The Japan Patent Office granted final approval for AIM ImmunoTech's Ampligen-based cancer treatment, including applications for pancreatic cancer.
More positive than 99% of claims this week
The newly approved Japanese patent provides protection for the treatment through December 20, 2039.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 87% of claims this week
AIM ImmunoTech shares retraced slightly on Friday despite having gained over 600% over the past 12 months.
More negative than 69% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company received final patent approval from the Japan Patent Office for its cancer treatment, though the stock saw a slight Friday dip after a large rally.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
8h ago
−79.3%
Price is moving against the score
$0.1901 vs $0.9180 close before publication (Mar 19) · not market-adjusted
AIM chart →
